Methods of treating OX40 medicated recall immune responses

Details Methods of treating OX40 medicated recall immune responses Methods of treating OX40 medicated recall immune responses

2007-11-06

2007-11-06

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S142100, C424S144100, C424S154100, C530S387100, C530S387300, C530S388150, C530S388700, C530S388750

Reexamination Certificate

active

10661358

ABSTRACT:
T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.

REFERENCES:
patent: 5759546 (1998-06-01), Weinberg et al.
patent: 6312700 (2001-11-01), Weinberg
patent: 6566082 (2003-05-01), Weinberg et al.
patent: 2002/0054873 (2002-05-01), Weinberg
patent: 2004/0009174 (2004-01-01), Arndt et al.
patent: WO 95/21251 (1995-08-01), None
patent: WO 99/42585 (1999-08-01), None
Basic Facts about Asthma, 2003, at cdc.gov/asthma/faqs.
Mellis, Med. J. Aust., 2002, 177: S78-S80.
Owens et al., Journal of Immunological Methods, 1994, 168: 149-165.
Evans, Dean E., et al., Engagement of OX40 Enhances Antigen-Specific CD4+T Cell Mobilization/Memory Development and Humoral Immunity: Comparison of αOX-40 with αCTLA-4,J. of Immunology,2001, 167:6804-6811.
Gramaglia, Irene, et al., Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses,J. of Immunology,1998, 161:6510-6517.
Gramaglia, Irene, et al., The OX40 Constimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion,J. of Immunology,2000, 165:3043-3050.
Kjaergaard, Jorgen, et al., Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor,J. of Immunology,2001, 167: 6669-6677.
Maxwell, Joseph R., et al., Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion,J. of Immunology,2000, 164:107-112.
Pan, Ping-Ying, OX40 Ligation Enhances Primary and Memory Cytoxic T Lymphocyte Responses in an Immunotherapy for Hepatic Colon Metastases,Molecular Therapy,6(4):528-536 (2002).
Weatherill, Amy R., et al., OX40 Ligation Enhances Cell Cycle Turnover of Ag-Activated CD4 T Cell in Vivo,Cellular Immunology,209, 63-75 (2001).
Weinberg, Andrew D., et al., Blocking OX-40/OX-40 Ligand Interaction In Vitro and In Vivo Leads to Decreased T Cell Function and Amelioration of Experimental Allergic Encephalomyelitis,J. of Immunology,1999, 162: 1818-1826.
Weinberg, Andrew D., Ox40: Targeted Immunotherapy-Implications for Tempering Autoimmunity and enhancing Vaccines,TRENDS in Immunology,20(2):102-109 (Feb. 2002).
Yoshioka, T., et al., Contribution of OX40/OX40 Ligand Interaction to the Pathogenesis of Rheumatoid Arthritis, Eur. J. Immunol., 30:2815-2823 (2000).

Affiliated with

Also associated with

Rating

Methods of treating OX40 medicated recall immune responses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating OX40 medicated recall immune responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating OX40 medicated recall immune responses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3873581